¹Ù·½QQ
¹Ù·½Î¢ÐÅ
ÊÖ»ú°æ
ÄúµÄλÖãºÊ×Ò³ >˶ʿÉúµ¼Ê¦>ÁÙ´²ÖÐÒ©·½Ïò>ÏêϸÄÚÈÝ

ÁÙ´²ÖÐÒ©·½Ïò

öÄÀñƼ

7ed54810934f4edea020d17a8b6fe699.png

Ò»¡¢¸öÈ˼ò½é

öÄÀñƼ£¬¸±½ÌÊÚ£¬Ë¶Ê¿Éúµ¼Ê¦£¬Ò©Ê¹ÜÀí½ÌÑÐÊÒÖ÷ÈΣ¬ËÄ´¨Ê¡ÖÐÒ©¼à¹Ü¿ÆÑ§Ñо¿»ùµØÖ÷ÈΣ¬µÚÆßÅúÈ«¹úÃûÀÏÖÐҽҩר¼ÒѧÊõ¾­Ñé¼Ì³Ð¹¤×÷¼Ì³ÐÈË¡£¼æÈιú¼ÊÖÐÒ½Ò©¹æ·¶Ñо¿Ñ§»á£¨GP-TCM RA£©·¨¹æ×éÁªºÏÖ÷ϯ¡¢ÖлªÖÐҽҩѧ»áÖÐÒ©²úÒµ·¢Õ¹Óë¼à¹Ü¿ÆÑ§Ñо¿¸ß¶ËÖÇ¿â³ÉÔ±¡¢Öйúҩѧ»á¼à¹Ü¿ÆÑ§Óë¹ú¼Ê¹æ·¶×¨ÒµÎ¯Ô±»áµÚÒ»½ìίԱ»áίԱµÈ£¬µ£ÈΡ¶ÖвÝÒ©¡·ÇàÄê±àί¼°¡¶Phytomedicine¡·¡¶Frontiers in pharmacology¡·¡¶Chinese medicine¡·¡¶ÖйúÖÐÒ©ÔÓÖ¾¡·µÈÉó¸åÈË¡£Ö÷³Ö¹ú¼ÒÉç»á¿ÆÑ§»ù½ð¡¢¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð¡¢Öйú²©Ê¿ºó»ù½ð¡¢Ê¡¿Æ¼¼ÌüµÈ¸÷¼¶×ÝÏò¿ÎÌâºÍÆóҵίÍпÎÌ⣻»ñÖлªÖÐҽҩѧ»á¿ÆÑ§¼¼Êõ½±¡¤Õþ²ßÑо¿½±£¬ÔÚ¹úÄÚÍâȨÍþÆÚ¿¯·¢±íѧÊõÂÛÎÄ70ÓàÆª¡£Ñо¿·½Ïò£º

1.ÖÐÒ©¼à¹Ü¿ÆÑ§Óë¹ú¼Ê»¯Ñо¿£ºÖÂÁ¦ÓÚ¶àѧ¿Æ½»²æÈÚºÏÑо¿£¬Í¨¹ýÖÐҩѧÓë¹ÜÀíѧ¡¢·¨Ñ§µÈÉç»á¿ÆÑ§Ñ§¿Æ½»²æ£¬¾Û½¹ÎÒ¹úÖÐÒ©È«ÉúÃüÖÜÆÚ¹ÜÀí¡¢Å·ÃÀÖ²ÎïÒ©¼à¹ÜµÈ£¬¿ªÕ¹ÖÐÒ©¼à¹Ü¿ÆÑ§ÓëÖÐÒ©¹ú¼Ê»¯Ñо¿Ì½Ë÷£»

2.ÖÐҩЧӦÓë»úÀíÑо¿£ºÍ¨¹ýÖÐҩѧÓë·Ö×ÓÉúÎïѧ¡¢ÉúÎﻯѧµÈѧ¿Æ½»²æ£¬ÒÔÁÙ´²ÐèÇóΪµ¼Ïò£¬¿ªÕ¹ÖÐҩЧӦ¼°»úÀíÑо¿¡£

ÓÊÏ䣺quliping@cdutcm.edu.cn

¶þ¡¢´ú±íÐԳɹû£¨¿Éº¬³Ðµ£ÏîÄ¿¡¢·¢±íÂÛÎÄ¡¢ÂÛÖø¡¢»ñ½±µÈ£©

£¨Ò»£©Ö÷³ÖÏîÄ¿

1.¹ú¼ÒÉç»á¿ÆÑ§»ù½ð£¬ÃæÏòÅ·Ã˵ÄÖÐÒ©¹ú¼Ê»¯Ö§³ÖÌåϵ¹¹½¨¼°¡°Öйú»°ÓÑо¿

2.¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð£¬»ùÓÚHNF1¦Á/PCSK9/LDLRÐźÅͨ·Ñо¿ÐÄѪ¿µÐ­Í¬ËûÍ¡Ààҩζ¯ÂöÖàÑùÓ²»¯µÄЧӦ»úÖÆ

3.ËÄ´¨Ê¡×ÔÈ»¿ÆÑ§»ù½ð½Ü³öÇàÄê¿ÆÑ§»ù½ðÏîÄ¿£¬ÐÄѪ¿µµ÷¿ØÄÚÆ¤Ï¸°û/Ðļ¡Ï¸°û¡°½»»¥¶Ô»°¡±±£»¤°¢Ã¹ËØÐÄѪ¹Ü¶¾ÐԵĻúÖÆÑо¿

4.ËÄ´¨Ê¡¿Æ¼¼ÌüÈí¿ÆÑ§Ñо¿ÏîÄ¿£¬ÒÔÅ·Ã˲ÝҩרÂÛΪÇÐÈëµãµÄÖÐÒ©¹ú¼Ê»¯Ñо¿

5.ËÄ´¨Ê¡Éç»á¿ÆÑ§ÖصãÑо¿»ùµØ?ËÄ´¨ÖÐÒ½Ò©·¢Õ¹Ñо¿ÖÐÐÄÏîÄ¿£¬Ò©Æ·¼à¹Ü¿ò¼ÜÏÂÒ©²ÄÓëÖÐÒ©ÒûƬµÄ¹ÜÀíÏÖ×´¡¢ÎÊÌâÓë¶Ô²ß

£¨¶þ£©·¢±íÂÛÎÄ

1.Liu J, Liu H, Deng L, Wang T, Li L, Chen Y, Qu L*, Zou W. Protective Role of Dioscin against Doxorubicin-Induced Chronic Cardiotoxicity: Insights from Nrf2-GPX4 Axis-Mediated Cardiac Ferroptosis. Biomolecules. 2024,14(4):422. doi: 10.3390/biom14040422.

2.Li X, Liang J, Qu L*, Liu S, Qin A, Liu H, Wang T, Li W, Zou W*. Exploring the role of ferroptosis in the doxorubicin-induced chronic cardiotoxicity using a murine model. Chem Biol Interact. 2022,363:110008. doi: 10.1016/j.cbi.2022.110008.

3.Qu L, Li X, Xiong Y, Wang Z, Zhou Y, Zou W, Tang J, Wang M. Opportunities and hurdles to European market access for multi-herbal traditional Chinese medicine products: An analysis of EU regulations for combination herbal medicinal products. Pharmacol Res. 2022,186:106528. doi: 10.1016/j.phrs.2022.106528

4.À,ÐìÓÀµ¤,öÄÀñƼ*,ÀîÐãÀö,»ÆÐÀÔÃ,ÍõÊÀÓî*.»ùÓÚ×¢²áÉóÅúÊý¾Ý·ÖÎöÎÒ¹ú¶ù¿ÆÖÐÒ©ÐÂÒ©Ñз¢ÏÖ×´.ÖйúҩѧÔÓÖ¾,2025,60(07):763-771.

5.öÄÀñƼ,ÌÆ½¡Ôª,ÕÅÀÚ,ÑîÖÒÆæ,ԪΨ°²,ÍõÍ£,ÕÅÓÀÎÄ,Àî¹¢.ÎÒ¹úÖÐÒ©×¢²á·ÖÀàµÄÀúÊ·Ñݱ䡢ÏÖ×´ÓëÎÊÌâ.ÖйúÖÐÒ©ÔÓÖ¾,2022,47(02):562-568.

£¨Èý£©½Ì²Ä/ÂÛÖø

1.¸ßµÈԺУ¡°Ê®ËÄÎ塱´´Ð½̲ġ¶ÖÐÒ©¼à¹Ü¿ÆÑ§¡·£¬ÈËÃñÎÀÉú³ö°æÉ磬2024£¬¸±Ö÷±à

2.È«¹úÖÐÒ½Ò©ÐÐÒµ¸ßµÈ½ÌÓý¡°Ê®ËÄÎ塱¹æ»®½Ì²Ä¡¶Ò©Ê¹ÜÀíѧ¡·£¬ÖйúÖÐÒ½Ò©³ö°æÉ磬2021£¬±àί

3.¸ßµÈÖÐҽҩԺУ¡°Ê®ËÄÎ塱¹æ»®ÐÂÐÎ̬½Ì²Ä¡¶ÖÐҩѧ¡·£¨µÚ2°æ£©£¬2024£¬±àί

£¨ËÄ£©»ñ½±

1.ÖлªÖÐҽҩѧ»á£¬¿ÆÑ§¼¼Êõ½±¡¤Õþ²ßÑо¿½±£¨Ò»µÈ½±)£¬»ùÓÚÖÐÒ½Ò©¹ú¼Ê·¢Õ¹µÄÖÐÒ©Å·ÃË×¢²áÕþ²ßÑо¿ÓëÓ¦ÓÃʵ¼ù£¨2/4£©£¬2020

2.µÚ¶þ½ìÆÕͨ±¾¿Æ¸ßУ½Ìʦ½Ìѧ´´Ð´óÈü£¬ÈýµÈ½±£¬»ùÓÚ¡°ÈýЭͬ¡¢Á½¸Ä½ø¡±µÄҩʹÜÀíѧ»ìºÏʽ½Ìѧ¸Ä¸ï´´ÐÂÓëʵ¼ù£¨1/4£©£¬2022

ÖÕÉó£ºÒ©Ñ§Ôº×ܹÜÀíÕ˺Å